[1] State Council of the People’s Republic of China. Regulations on the supervision and administration of medical devices[EB/OL]. (2021-03-18)[2022-09-08]. http://www.gov.cn/zhengce/content/2021-03/18/content_5593739.htm#. [2] U.S. Food & Drug Administration. Medical device safety action plan: protecting patients, promoting public health[EB/OL]. (2021-01-05)[2022-09-08]. https://www.fda.gov/media/112497/download. [3] TENG YY, LI CQ, XU Y, et al.Progress in the application of real-world data in post-market surveillance of medical devices[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(3): 233-238. [4] BROWN JC, TUURI RE, AKHTER S, et al.Lacerations and embedded needles caused by epinephrine autoinjector use in children[J]. Annals of Emergency Medicine, 2016, 67(3): 307-317. [5] DUGGIRALA HJ, HERZ ND, CAñOS DA, et al. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System[J]. Pharmacoepidemiol Drug Saf, 2012, 21(1): 87-93. [6] Agency for Healthcare Research and Quality. Using claims data to perform surveillance for surgical site infection: the devil is in the details[EB/OL]. (2014-06-30)[2022-09-08]. https://www.ahrq.gov/hai/patient-safety-resources/advances-in-hai/hai-article13.html. [7] CALLAHAN A, FRIES JA, RE C, et al.Medical device surveillance with electronic health records[J]. NPJ Digital Medicine, 2019, 2: 94. [8] RESNIC FS, MAJITHIA A, MARINAC-DABIC D, et al.Registry-based prospective, active surveillance of medical-device safety[J]. N Engl J Med, 2017, 376(6): 526-535. [9] CHUGHTAI B, MAO J, MATHENY ME, et al.Long-term safety with sling mesh implants for stress incontinence[J]. J Urol, 2021, 205(1): 183-190. [10] CHEN Z, LI B, SHI LW, et al.Introduction of common data model in United States FDA mini-sentinel and its enlightenment to China[J]. China Pharmacy(中国药房), 2013, 24(41): 3. [11] BUCHER BT, SHI J, FERRARO JP, et al.Portable automated surveillance of surgical site infections using natural language processing: development and Validation[J]. Ann Surg, 2020, 272(4): 629-636. [12] GALPER BZ, BEERY DE, LEIGHTON G, et al.Comparison of adverse event and device problem rates for transcatheter aortic valve replacement and Mitraclip procedures as reported by the Transcatheter Valve Therapy Registry and the Food and Drug Administration postmarket surveillance data[J]. American Heart Journal, 2018, 198: 64-74. [13] BRANCH-ELLIMAN W, STRYMISH J, KUDESIA V, et al.Natural language processing for real-time catheter-associated urinary tract infection surveillance: results of a pilot implementation trial[J]. Infection Control & Hospital Epidemiology, 2015, 36(9): 1004-1010. [14] CHUNG G, ETTER K, YOO A.Medical device active surveillance of spontaneous reports: A literature review of signal detection methods[J]. Pharmacoepidemiol Drug Saf, 2020, 29(4): 369-379. [15] COSTE A, WONG A, BOKERN M, et al. Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review[J/OL]. Pharmacoepidemiol Drug Saf. (2022-10-02)[2022-11-11]. https://onlinelibrary.wiley.com/doi/epdf/10.1002/pds.5548?utm_medium=referral&utm_source=baidu_scholar&utm_campaign=RWA17109&utm_content=Global_Marketing_HS_Pharmacoepidemiology. [16] CHEN Y, GUO J, JIANG D, et al.Database mining and exploration and analysis of adverse drug reaction signals (Part 2)[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2006, 15(2): 104-107. [17] RESNIC FS, GROSS TP, MARINAC-DABIC D, et al.Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices[J]. Jama-Journal of the American Medical Association, 2010, 304(18): 2019-2027. [18] RASSEN JA, SCHNEEWEISS S.Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system[J]. Pharmacoepidemiology and Drug Safety, 2012, 21: 41-49. [19] WALD A.Sequential tests of statistical hypotheses[J]. Annals of Mathematical Statistics, 1945, 16(2): 117-186. [20] HARDOON SL, LEWSEY JD, GREGG PJ, et al.Continuous monitoring of the performance of hip prostheses[J]. J Bone Joint Surg Br, 2006, 88(6): 716-720. [21] HARDOON SL, LEWSEY JD, VAN DER MEULEN JH. Continuous monitoring of long-term outcomes with application to hip prostheses[J]. Stat Med, 2007, 26(28): 5081-5099. [22] CAFRI G, GRAVES SE, SEDRAKYAN A, et al.Postmarket surveillance of arthroplasty device components using machine learning methods[J]. Pharmacoepidemiology and Drug Safety, 2019, 28(11): 1440-1447. [23] REPS JM, GARIBALDI JM, AICKELIN U, et al.A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations[J]. J Biomed Inform, 2015, 56: 356-368. [24] ROSS JS, BATES J, PARZYNSKI CS, et al.Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter-defibrillators[J]. Med Devices (Auckl), 2017, 10: 165-188. [25] PANE J, VERHAMME KMC, VILLEGAS D, et al.Challenges associated with the safety signal detection process for medical devices[J]. Medical Devices (Auckland, N.Z.), 2021, 24(14): 43-57. [26] ZHOU L, OUYANG W, LI G, et al.Analysis of the current situation of registry studies in China[J]. Chinese Journal of Evidence-based Medicine(中国循证医学杂志), 2019, 19(6): 702-707. [27] YU Y, ZHAI W, LIN W, et al.Current status and analysis of overseas and domestic medical device registry study[J]. China Medical Device Information(中国医疗器械信息), 2021, 27(1): 1-3,167. [28] National Medical Products Administration. Pilot work plan for unique identification system for medical devices[EB/OL]. (2019-07-01)[2022-11-11]. https://udi.nmpa.gov.cn/toDetail.html?infoId=30&CatalogId=2. [29] SHEN C, SONG Y, ZHAO Y, et al.Thoughts on constructing vigilance system of Chinese medical device in the new era[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 697-701. [30] TAN J, LIU C, HUANG S, et al.Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(1): 13-17,31. [31] National Medical Products Administration. Circular of the State Food and Drug Administration on the Implementation of the Second Batch of Key Projects of the Scientific Action Plan for Drug Administration in China[EB/OL]. (2021-06-28)[2022-09-08]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20210628172854126.html. |